Journal profile · Oncology
EJC SUPPLEMENTS
ISSN 1359-6349 · eISSN 1878-1217 · Elsevier · ENGLAND · Monthly
EJC SUPPLEMENTS: diamond open access (no APC); no APC; review about 3.7 months (community reports); community-reported acceptance: about 50.71%; 0 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
EJC SUPPLEMENTS is published by Elsevier. By OpenAlex counts of its recent articles, its largest topics are Breast Cancer Treatment Studies, Breast Lesions and Carcinomas and Colorectal Cancer Treatments and Studies, together about 30.1% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
EJC Supplements is an open access companion journal to the European Journal of Cancer. As an open access journal, all published articles are subject to an Article Publication Fee. Immediately upon publication, all articles in EJC Supplements are made openly available through the journal's websites.EJC Supplements will consider for publication the proceedings of scientific symposia, commissioned thematic issues, and collections of invited articles on preclinical and basic cancer research, translational oncology, clinical oncology and cancer epidemiology and prevention.Authors considering the publication of a supplement in EJC Supplements are requested to contact the Editorial Office of the EJC to discuss their proposal with the Editor-in-Chief.EJC Supplements is an official journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European CanCer Organisation (ECCO) and the European Society of Mastology (EUSOMA).
From the journal's Aims & Scope
Research area (LetPub): Oncology
Editor-in-chief Alexander M.M. EggermontPublisher website
Editorial board by country: none in mainland China; most named France 18, Netherlands 16, United Kingdom 14, Italy 14, Canada 8 (108 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology17.4%
- Breast Lesions and CarcinomasMedicine7.4%
- Colorectal Cancer Treatments and StudiesMedicine5.4%
- Lung Cancer Treatments and MutationsMedicine5.1%
- HER2/EGFR in Cancer ResearchMedicine4.6%
- Gastric Cancer Management and OutcomesMedicine4.6%
- Cancer survivorship and careMedicine4.1%
- Head and Neck Cancer StudiesMedicine4.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Oncology | Q3 | 219/366 | — |
| Cancer Research | Q4 | 162/214 | — |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 3.3LetPub ·
- SJR 2026-06
- 0.57LetPub ·
- SNIP 2026-06
- 0.34LetPub ·
- h-index
- 22LetPub ·
- h-index
- 44OpenAlex ·
- i10-index
- 335OpenAlex ·
- 2-year mean citedness
- 0.4OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 15,230 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 5 | 5 | 276 |
| 2025 | 0 | 0 | 443 |
| 2024 | 0 | 0 | 463 |
| 2023 | 0 | 0 | 608 |
| 2022 | 0 | 0 | 624 |
| 2021 | 4 | 4 | 751 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
Too few articlesOnly 2 articles from the last 24 months carry both submission and acceptance dates, too few for a median
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 3.7 monthsLetPub ·
- Average acceptance (community reports)
- 50.71%LetPub ·
- Submission to publication (journal-reported)
- about 9 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Diamond open access (no APC)DOAJ
Every article is open access and authors pay no article processing charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | No APC | No | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 0 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare5 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Reference style
- Numbered, in order of citation
- First submission
- Free format: the journal's layout is not required
- Highlights
- Optional
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process. Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Monthly
- ISSN
- 1359-6349
- Electronic ISSN
- 1878-1217
- Society / sponsor
- European Organisation for Research and Treatment of Cancer
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about EJC SUPPLEMENTS
How long does peer review take at EJC SUPPLEMENTS?
Authors report an average review time of about 3.7 months; the community-reported acceptance is “about 50.71%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of EJC SUPPLEMENTS?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Reference style: Numbered, in order of citation; First submission: Free format: the journal's layout is not required; Highlights: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of EJC SUPPLEMENTS based?
Of the 108 board members whose country the journal's board page names, none are in mainland China; the countries named most often are France (18), Netherlands (16) and United Kingdom (14). Counted from the institutions listed on the board page; for reference only.
Which databases index EJC SUPPLEMENTS?
According to LetPub and DOAJ records, EJC SUPPLEMENTS is indexed in Scopus and DOAJ.
Is EJC SUPPLEMENTS open access, and what is the APC?
EJC SUPPLEMENTS is a diamond open-access journal (no APC). It charges no article processing charge.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-30). Last updated: .